115 related articles for article (PubMed ID: 15084702)
61. [Gene therapy of children with X-linked severe combined immune deficiency: efficiency and complications].
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Med Sci (Paris); 2004 Jan; 20(1):115-7. PubMed ID: 14770374
[No Abstract] [Full Text] [Related]
62. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.
von Kalle C; Fehse B; Layh-Schmitt G; Schmidt M; Kelly P; Baum C
Semin Hematol; 2004 Oct; 41(4):303-18. PubMed ID: 15508116
[TBL] [Abstract][Full Text] [Related]
63. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
[TBL] [Abstract][Full Text] [Related]
64. Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology.
Mavilio F; Ferrari G
EMBO Rep; 2008 Jul; 9 Suppl 1(Suppl 1):S64-9. PubMed ID: 18578029
[No Abstract] [Full Text] [Related]
65. Risks of gene therapy should be weighed against lack of alternatives for many diseases.
MacLaren RE; Ali RR; Thrasher AJ
BMJ; 2005 Apr; 330(7494):791. PubMed ID: 15802733
[No Abstract] [Full Text] [Related]
66. [Prevention of insertional mutagenesis. Inevitable or manageable?].
Baum C
Pharm Unserer Zeit; 2011 May; 40(3):248-52. PubMed ID: 21698614
[No Abstract] [Full Text] [Related]
67. Gene therapy: two steps forward, one step back.
Johnston J; Baylis F
CMAJ; 2004 Jun; 170(12):1785-6. PubMed ID: 15184327
[No Abstract] [Full Text] [Related]
68. Retroviral gene therapy--where now?
Günzburg WH
Trends Mol Med; 2003 Jul; 9(7):277-8. PubMed ID: 12900211
[No Abstract] [Full Text] [Related]
69. What are the consequences of the fourth case?
Baum C
Mol Ther; 2007 Aug; 15(8):1401-2. PubMed ID: 17646833
[No Abstract] [Full Text] [Related]
70. Telomerization of mammalian cells and transplantation of telomerized cells in immunodeficient mice.
Hornsby PJ
Methods Mol Biol; 2004; 240():147-66. PubMed ID: 14970409
[No Abstract] [Full Text] [Related]
71. Sex determination: zinc fingers point in the wrong direction.
Craig I
Trends Genet; 1990 May; 6(5):135-7. PubMed ID: 2114681
[No Abstract] [Full Text] [Related]
72. T lymphocytes are not immune.
Dotti G
Mol Ther; 2013 Jun; 21(6):1114-5. PubMed ID: 23728254
[No Abstract] [Full Text] [Related]
73. Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.
Hackett CS; Geurts AM; Hackett PB
Genome Biol; 2007; 8 Suppl 1(Suppl 1):S12. PubMed ID: 18047689
[TBL] [Abstract][Full Text] [Related]
74. Gene therapy in The Netherlands: highlights from the Low Countries.
Schenk-Braat EA; Kaptein LC; Hallemeesch MM; Bangma CH; Hoeben RC
J Gene Med; 2007 Oct; 9(10):895-903. PubMed ID: 17721875
[TBL] [Abstract][Full Text] [Related]
75. Encapsulation of nucleic acids and opportunities for cancer treatment.
Brannon-Peppas L; Ghosn B; Roy K; Cornetta K
Pharm Res; 2007 Apr; 24(4):618-27. PubMed ID: 17372693
[TBL] [Abstract][Full Text] [Related]
76. Gene targeting: roadmap to future therapies.
Huber LC; Pap T; Müller-Ladner U; Gay RE; Gay S
Curr Rheumatol Rep; 2004 Oct; 6(5):323-5. PubMed ID: 15355741
[No Abstract] [Full Text] [Related]
77. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
78. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
79. Gene therapy. RAC's advice: proceed with caution.
Kaiser J
Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
[No Abstract] [Full Text] [Related]
80. Risks and benefits of gene therapy.
Noguchi P
N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
